8-KRegulation FDExhibits & Filings

PFIZER INC 8-K Report, Regulation FD Disclosure (Dec 16, 2025)

Filed December 16, 2025For Securities:PFE

Summary

Pfizer Inc. (PFE) has filed an 8-K report detailing updated financial guidance. The company announced revised full-year 2025 revenue guidance and provided its full-year 2026 guidance, while reaffirming all other components of its 2025 financial outlook. This update is being communicated to investors via a press release filed as an exhibit to this report. Investors should pay close attention to the specifics of the revenue revision for 2025 and the outlook for 2026 as provided in the accompanying press release. While other 2025 guidance components remain unchanged, the revenue adjustments could signal shifts in market dynamics or product performance. The 2026 guidance will offer a forward-looking perspective on Pfizer's expected financial trajectory.

Key Highlights

  • 1Pfizer issued revised full-year 2025 revenue guidance.
  • 2Pfizer provided its full-year 2026 financial guidance.
  • 3All other components of Pfizer's full-year 2025 financial guidance were reaffirmed.
  • 4The information was disclosed via a press release dated December 16, 2025.
  • 5The press release is furnished as Exhibit 99.1 to the 8-K filing.
  • 6This filing is for informational purposes under Regulation FD.
  • 7Includes the Cover Page Interactive Data File in XBRL format.

Frequently Asked Questions

The main purpose of this 8-K filing is to disclose updated financial guidance from Pfizer Inc. This includes a revision to its full-year 2025 revenue guidance and the provision of its full-year 2026 guidance to investors.

No, the filing states that Pfizer is reaffirming all other components of its full-year 2025 financial guidance, with only revenue guidance being revised.

The detailed financial guidance is provided in the press release issued by Pfizer on December 16, 2025, which is included as Exhibit 99.1 to this 8-K filing.

No, this 8-K filing does not contain new financial statements. It primarily serves as a Regulation FD disclosure to provide updated financial guidance through an accompanying press release.